AstraZeneca's 2026 Interim Report: Profit Beats Expectations, China Revenue Reaches RMB 23.7 Billion

On July 27, AstraZeneca released its latest financial results for the first half of 2026.

According to a Reuters analysis, although AstraZeneca’s second-quarter profit exceeded market expectations, recent setbacks in multiple clinical trials have kept investor focus squarely on its R&D pipeline. The pharmaceutical company reiterated its annual and long-term guidance on Monday to reassure investors.

The global pharmaceutical industry is currently facing widespread pricing pressures, yet strong demand for oncology and rare disease drugs continues to drive revenue growth. However, following an unexpected failure in a clinical trial this month, investors are closely watching whether this setback could impact the drugmaker’s 2030 revenue target.

AstraZeneca set a goal in 2024 to achieve annual revenue of $80 billion by 2030. JPMorgan analysts said on Monday that the company’s second-quarter profit beat market expectations and revenue met forecasts, making this target achievable.

As of 8 a.m. GMT, AstraZeneca’s share price rose 1.5%, though it has declined approximately 7% year-to-date. Over a longer horizon, however, the company has delivered strong performance under CEO Pascal Soriot, who has led the firm for 14 years, with its stock price now more than quadrupling from its initial level during his tenure.

Diversified business portfolio

AstraZeneca’s diversified presence across therapeutic areas and marketed products, combined with a generally high success rate in clinical trials, constitutes its key competitive advantage. However, after recent clinical setbacks with the neurological drug Wainua and the investigational breast cancer therapy camizestrant, two upcoming late-stage oncology trial results will serve as a critical test of Soriot’s strategic vision.

In an official statement, the company said: 'We remain confident in the strength of our R&D pipeline, with over 20 high-value clinical data readouts expected within the next 18 months.'

AstraZeneca also disclosed positive results from another late-stage gastric cancer clinical trial, but a study of its rare disease drug Ultomiris failed to meet its primary endpoint—this trial targeted patients suffering from a life-threatening complication following stem cell transplantation.

Adam Vettese, analyst at eToro, noted: 'The company’s growth momentum has clearly slowed, and the remaining pivotal oncology clinical trial data due later this year will remain a central focus for investors.'

Maintains 2026 financial outlook

AstraZeneca maintained its previous guidance: core earnings per share for 2026 are expected to grow in the low double digits, and total revenue is projected to increase in the mid-to-high single digits, both on a constant-currency basis. The company’s revenue and profit growth last year were approximately 8% and 11%, respectively.

Core earnings per share rose to USD 2.63 in the second quarter, driven by lower tax expenses; total revenue increased by 5% year-over-year to USD 15.38 billion. AstraZeneca's consensus market expectations were USD 2.48 per share and USD 15.39 billion in revenue, respectively.

According to JPMorgan data, oncology sales grew 15% year-over-year, boosted by sales of the blood cancer drug Calquence, while rare disease revenues rose 8%. Both segments outperformed market expectations.

Additionally, the company raised its peak sales forecast for its investigational respiratory drug tozorakimab from the previous estimate of USD 3 billion to over USD 5 billion.

By region,In the first half of 2026, revenue from the U.S. market reached USD 12.89 billion (+8%); revenue from China amounted to USD 3.51 billion (−5%), accounting for 11% of AstraZeneca’s global sales.

From a product perspective,Farxiga (dapagliflozin) generated USD 3.998 billion in revenue (−11%), primarily impacted by patent expiration, yet remained AstraZeneca’s top-selling drug in the first half of the year. Tagrisso (osimertinib) and Imfinzi (durvalumab) ranked second and third, with revenues of USD 3.775 billion (+6%) and USD 3.548 billion (+29%), respectively.

6695 Views